209 related articles for article (PubMed ID: 33174368)
21. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
[TBL] [Abstract][Full Text] [Related]
22. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
23. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
Wang Y; Wang M; Ni Y; Liang Z
Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
[No Abstract] [Full Text] [Related]
24. Low-Molecular-Weight Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Arthroscopic Surgery and Anterior Cruciate Ligament Reconstruction: A Meta-analysis of Randomized Controlled Trials.
Zhu J; Jiang H; Marshall B; Li J; Tang X
Am J Sports Med; 2019 Jul; 47(8):1994-2002. PubMed ID: 30113231
[TBL] [Abstract][Full Text] [Related]
25. Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.
Schoot RA; Kremer LC; van de Wetering MD; van Ommen CH
Cochrane Database Syst Rev; 2013 Sep; (9):CD009160. PubMed ID: 24026801
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study.
Vadhan-Raj S; McNamara MG; Venerito M; Riess H; O'Reilly EM; Overman MJ; Zhou X; Vijapurkar U; Kaul S; Wildgoose P; Khorana AA
Cancer Med; 2020 Sep; 9(17):6196-6204. PubMed ID: 32663379
[TBL] [Abstract][Full Text] [Related]
27. Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines.
Fontana P; Casini A; Robert-Ebadi H; Glauser F; Righini M; Blondon M
Swiss Med Wkly; 2020 Jun; 150():w20301. PubMed ID: 32640479
[TBL] [Abstract][Full Text] [Related]
28. Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery.
Di Nisio M; Peinemann F; Porreca E; Rutjes AW
Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD009658. PubMed ID: 26091835
[TBL] [Abstract][Full Text] [Related]
29. Anticoagulation for perioperative thromboprophylaxis in people with cancer.
Matar CF; Kahale LA; Hakoum MB; Tsolakian IG; Etxeandia-Ikobaltzeta I; Yosuico VE; Terrenato I; Sperati F; Barba M; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009447. PubMed ID: 29993117
[TBL] [Abstract][Full Text] [Related]
30. Anticoagulation for people with cancer and central venous catheters.
Kahale LA; Tsolakian IG; Hakoum MB; Matar CF; Barba M; Yosuico VE; Terrenato I; Sperati F; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006468. PubMed ID: 29856471
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis and systematic review of randomized controlled trials assessing the role of thromboprophylaxis after vascular surgery.
Haykal T; Zayed Y; Kerbage J; Deliwala S; Long CA; Ortel TL
J Vasc Surg Venous Lymphat Disord; 2022 May; 10(3):767-777.e3. PubMed ID: 34508872
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
Robertson L; Strachan J
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
[TBL] [Abstract][Full Text] [Related]
33. Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery-Systematic review and meta-analysis.
Presume J; Ferreira J; Ribeiras R; Mendes M
J Thromb Haemost; 2022 Dec; 20(12):2930-2938. PubMed ID: 36128769
[TBL] [Abstract][Full Text] [Related]
34. Extended thromboprophylaxis following major abdominal/pelvic cancer-related surgery: A systematic review and meta-analysis of the literature.
Knoll W; Fergusson N; Ivankovic V; Wang TF; Caiano L; Auer R; Carrier M
Thromb Res; 2021 Aug; 204():114-122. PubMed ID: 34175749
[TBL] [Abstract][Full Text] [Related]
35. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
Khan F; Rahman A; Carrier M; Kearon C; Weitz JI; Schulman S; Couturaud F; Eichinger S; Kyrle PA; Becattini C; Agnelli G; Brighton TA; Lensing AWA; Prins MH; Sabri E; Hutton B; Pinede L; Cushman M; Palareti G; Wells GA; Prandoni P; Büller HR; Rodger MA;
BMJ; 2019 Jul; 366():l4363. PubMed ID: 31340984
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry.
Donath L; Lützner J; Werth S; Kuhlisch E; Hartmann A; Günther KP; Weiss N; Beyer-Westendorf J
Br J Clin Pharmacol; 2012 Dec; 74(6):947-58. PubMed ID: 22515679
[TBL] [Abstract][Full Text] [Related]
37. Primary Thromboprophylaxis in Ambulatory Pancreatic Cancer Patients Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Frere C; Crichi B; Bournet B; Canivet C; Abdallah NA; Buscail L; Farge D
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722064
[TBL] [Abstract][Full Text] [Related]
38. The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: A systematic review and meta-analysis of randomized controlled trials.
Abatzis-Papadopoulos M; Tigkiropoulos K; Nikas S; Papoutsis I; Kostopoulou O; Stavridis K; Karamanos D; Lazaridis I; Saratzis N
Orthop Traumatol Surg Res; 2023 Apr; 109(2):103364. PubMed ID: 35817368
[TBL] [Abstract][Full Text] [Related]
39. Benefits and harms of direct oral anticoagulation and low molecular weight heparin for thromboprophylaxis in patients undergoing non-cardiac surgery: systematic review and network meta-analysis of randomised trials.
Marcucci M; Etxeandia-Ikobaltzeta I; Yang S; Germini F; Gupta S; Agarwal A; Ventresca M; Tang S; Morgano GP; Wang M; Ahmed MM; Neumann I; Izcovich A; Criniti J; Popoff F; Devereaux PJ; Dahm P; Anderson D; Lavikainen LI; Tikkinen KAO; Guyatt GH; Schünemann HJ; Violette PD
BMJ; 2022 Mar; 376():e066785. PubMed ID: 35264372
[TBL] [Abstract][Full Text] [Related]
40. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis.
Ben-Aharon I; Stemmer SM; Leibovici L; Shpilberg O; Sulkes A; Gafter-Gvili A
Acta Oncol; 2014 Sep; 53(9):1230-7. PubMed ID: 25162954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
